Brenda Rodriguez

Brenda Rodriguez, PA-C CV

A.T. Still University (09/2023)

• Master of Science in Physician Assistant Studies

University of California, San Diego (06/2018)

• Bachelor of Science in Human Biology Minor in Psychology

PROFESSIONAL MEMBERSHIPS AND CERTIFICATIONS

• California Physician Assistant License Issued 11/2023 - current

• ACLS Certification Issued 12/2021 - current

• BLS/CPR Certification Issued 02/2023 - current

• Medication Assisted Treatment (MAT) Training Issued 11/2021

• HIPAA Training Certificate Issued 2021

• San Diego Physician Assistant Society Current·

• Good Clinical Practice Issued 12/2023

More About Brenda Rodriguez, PA-C

GW Research, Inc. Gastroenterology: 353 Church Ave. Chula Vista, CA 91910

(2023 – current)
Clinical Rotation (6-week duration) 2022 - 2023
Neurosurgery, Flagstaff Medical Center, Level I Trauma Center (ICU included) Flagstaff, AZ
General Surgery, Arizona Thyroid & Parathyroid Surgery Scottsdale, AZ
Women’s Health, Steward Medical Group (L&D) Gilbert, AZ
Family Medicine, Clinica La Familia Glendale, AZ
Pediatrics, Clinica La Familia Mesa, AZ
Internal Medicine, Gila Internal Medicine and Geriatrics Tempe, AZ
Emergency Medicine, Cobre Regional Valley Medical Center, Level IV Trauma Globe, AZ
Inpatient Behavioral Health, Oasis Behavioral Health Hospital Chandler, AZ

Medical Scribe/Medical Assistant (2019 – 2021)
Ian M. Purcell Otoneurology clinic, San Diego

• Provided comprehensive patient care, including detailed history and intake, concise presentation to the supervising provider, and thorough charting.

• Worked in a complex healthcare setting, delivering high-quality care, and collaborating with a range of healthcare professionals, including supervising physicians, physician assistants, medical assistants, technicians, and administrative staff.

CLINICAL RESEARCH
Sub-Investigator: VP-VLY-686-3301Vanda: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis (Patient enrollment time-16 weeks) November 2019 – ongoing (90 screened/ 21 randomized)

Sub-Investigator: Braintree BLI5100-301: A Phase 3, Double-Blind, Randomized, Two-Phase, Active Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients With Erosive Esophagitis. November 2022-ongoing (30 screened/ 1 randomized)

Sub-Investigator: Braintree BLI5100-302: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients With Non-Erosive Reflux Disease. November 2022-ongoing (30 screened/ 4 randomized)

Sub-Investigator: Braintree BLI5100-303: A Phase 3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients With Gastroesophageal Reflux Disease August 2023- ongoing (11 screened, 11 randomized)

Sub-Investigator: Inventiva, 337HNAS20011: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis. (Patient enrollment time- 5 years) May 2022-ongoing (9 screened, 2 randomized)

Sub-Investigator: Celldex, CDX0159-08: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The "EvolvE" Study) September 2023-ongoing (2 screened, 1 randomized)

Sub-Investigator: Akero AK-US-001-0105: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis (2 screened) September 2023-ongoing

Sub-Investigator: Akero AK-US-001-0107: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Nonalcoholic Fatty Liver Disease (NAFLD) September 2023-ongoing

Sub-Investigator: CinDome CIN-102-123: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subject With Diabetic Gastroparesis. March 2024-ongoing.